Company intelligence / Profile preview
Zhejiang Teruisi Pharmaceutical Inc.
Huzhou, Zhejiang, Chinain.marketscreener.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company has multiple products in development, with its recombinant humanized anti-VEGF monoclonal antibody in Phase 3. TRS-005 received breakthrough therapy designation from China's NMPA in March 2024 for relapsed/refractory CD20-positive diffuse large B-cell lymphoma.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Monoclonal antibodiesAntibody-drug conjugatesBiosimilarsBiological products
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Zhejiang Teruisi Pharmaceutical Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Teruisi Pharmaceutical Inc..